Erlotinib (Hydrochloride)
Erlotinib Hydrochloride (CP-358774 Hydrochloride) inhibits purified EGFR kinase with an IC50 of 2 nM. Erlotinib (Hydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
Product Specifications
CAS Number
[183319-69-9]
Product Name Alternative
CP-358774 (hydrochloride) ; NSC 718781 (hydrochloride) ; OSI-774 (hydrochloride)
UNSPSC
12352005
Hazard Statement
H301, H413
Target
Autophagy; EGFR
Type
Reference compound
Related Pathways
Autophagy; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Erlotinib-Hydrochloride.html
Purity
99.99
Solubility
DMSO : 3.33 mg/mL (ultrasonic; warming; heat to 60°C) |H2O : < 0.1 mg/mL
Smiles
COCCOC1=CC2=NC=NC(NC3=CC=CC(C#C)=C3)=C2C=C1OCCOC.[H]Cl
Molecular Formula
C22H24ClN3O4
Molecular Weight
429.90
Precautions
H301, H413
References & Citations
[1]Moyer JD, et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. 1997 Nov 1;57 (21) :4838-48.|[2]Ali S, et al. Apoptosis-inducing effect of erlotinib is potentiated by 3,3'-diindolylmethane in vitro and in vivo using an orthotopic model of pancreatic cancer. Mol Cancer Ther, 2008, 7 (6), 1708-1719.|[3]Marchetti S, et al. Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-typ|[4]Adachi K, et al. Effects of erlotinib on lung injury induced by intratracheal administration of bleomycin (BLM) in rats. J Toxicol Sci. 2010 Aug;35 (4) :503-14.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
EGFR/ErbB1/HER1
Citation 01
Am J Transl Res. 2020 May 15;12 (5) :2295-2304. |Cell Rep Methods. 2023 Feb 21;3 (2) :100411.|Cell Rep Methods. 2023 Oct 23;3 (10) :100599.|Cell Rep. 2023 May 29;42 (6) :112570.|CNS Neurosci Ther. 2022 Jan;28 (1) :64-76.|Nat Immunol. 2022 Feb;23 (2) :251-261.|SSRN. 2025 Sep 25.|ACS Omega. 2025 Oct 29;10 (44) :52562–52575.|Acta Pharmacol Sin. 2021 Jan;42 (1) :108-114.|Adv Ther. 2024 Jul 18.|Allergy. 2025 May;80 (5) :1335-1347.|Anal Chim Acta. 2018 Nov 22:1032:138-146.|Bioact Mater. 2021 Nov 4;13:312-323.|Bioact Mater. 2024 May 11:38:384-398.|Biochem Biophys Res Commun. 2022 Dec 25;636 (Pt 1) :125-131.|Biochem Biophys Res Commun. 2024 Sep 19:733:150711.|Biochem Pharmacol. 2025 Jul 18:241:117183.|Bioengineering (Basel) . 2025 Oct 19;12 (10) :1121.|Biol Methods Protoc. 2025 Feb 13;10 (1) :bpaf012.|Biomaterials. 2022 Oct:289:121800.|Biomed Chromatogr. 2016 Jul;30 (7) :1150-4. |Biomed Chromatogr. 2024 Nov 7:e6039.|Biomed Pharmacother. 2024 Jun:175:116644.|Biomed Res Int. 2019 Nov 28;2019:2410845.|Bioorg Chem. 2025 Aug 9:164:108864.|bioRxiv. 2019 Sep.|bioRxiv. 2023 Oct 20:2023.10.19.563158.|bioRxiv. 2024 Dec 20:2024.12.19.629301.|bioRxiv. 2025 Sep 21.|bioRxiv. October 28, 2021.|Br J Cancer. 2023 Feb;128 (4) :678-690.|Breast Cancer Res Treat. 2025 Jun;211 (2) :467-478.|Cancer Cell. 2025 Jul 25:S1535-6108 (25) 00310-1.|Cancer Lett. 2025 Apr 10:217715.|Cancer Manag Res. 2024 May 28:16:507-525.|Cancer Med. 2019 Dec;8 (18) :7793-7808.|Cancer Med. 2024 May;13 (10) :e7083.|Cancer Res Treat. 2023 Jul;55 (3) :778-803.|Cancer Res Treat. 2023 Oct;55 (4) :1077-1086.|Cancer Res. 2024 Feb 1;84 (3) :479-492.|Cancers (Basel) . 2022 Jun 5;14 (11) :2807.|Cell Biol Toxicol. 2021 Apr;37 (2) :313-330.|Cell Death Differ. 2024 Sep;31 (9) :1140-1156.|Cell Death Dis. 2022 Dec 27;13 (12) :1075.|Cell Death Dis. 2022 Jan 13;13 (1) :55.|Cell Death Discov. 2025 May 17;11 (1) :241.|Cell Insight. 2022 Jun 16;1 (4) :100045.|Cell Rep Med. 2023 Feb 21;4 (2) :100911.|Cell Rep Med. 2025 Apr 2:102053.|Cell Rep. 2024 Mar 27;43 (4) :114002.|Cell Res. 2020 Oct;30 (10) :833-853. |Cell Syst. 2020 Nov 18;11 (5) :478-494.e9.|Commun Biol. 2021 Dec 13;4 (1) :1391.|Complutense University of Madrid. 2025.|Dev Cell. 2025 Sep 29:S1534-5807 (25) 00539-8.|Ecotoxicol Environ Saf. 2023 Jan 1:249:114386.|Ecotoxicol Environ Saf. 2024 Oct 15:285:117031.|EMBO J. 2025 Mar;44 (5) :1464-1487.|Exp Cell Res. 2020 Aug 1;393 (1) :112054.|Exp Cell Res. 2021 Feb 1;399 (1) :112424.|Front Pharmacol. 2018 Jun 21:9:660.|Front Pharmacol. 2022 Apr 8;13:879751.|Genome Med. 2021 Sep 1;13 (1) :142.|Harvard Medical School LINCS LIBRARY|Hum Reprod Open. 2025 May 14;2025 (3) :hoaf027.|Int J Biol Macromol. 2023 Oct 1:250:126147.|J Cancer. 2024 Mar 25;15 (10) :2891-2899.|J Cell Mol Med. 2020 Jan;24 (2) :1969-1979.|J Clin Invest. 2020 Mar 2;130 (3) :1417-1430.|J Control Release. 2024 Dec:376:829-841.|J Enzyme Inhib Med Chem. 2025 Dec;40 (1) :2501743.|J Exp Clin Cancer Res. 2021 Jan 9;40 (1) :25.|J Exp Clin Cancer Res. 2024 Nov 20;43 (1) :308.|J Invest Dermatol. 2019 Jan;139 (1) :224-234.|J Med Food. 2018 Jul;21 (7) :701-708.|J Nutr Biochem. 2023 Sep:119:109399.|J Pharm Anal. 2021 Dec;11 (6) :799-807.|Lung Cancer. 2024 Apr 11.|Mar Drugs. 2024 Sep 28;22 (10) :444.|Mol Cancer Res. 2019 Nov;17 (11) :2233-2243.|Mol Carcinog. 2022 Jul;61 (7) :664-676.|Mol Cell. 2022 Jul 7;82 (13) :2443-2457.e7.|Mol Cell. 2023 Dec 7;83 (23) :4334-4351.e7.|Mol Divers. 2025 Jun;29 (3) :2391-2405.|Mol Oncol. 2018 Mar;12 (3) :305-321.|Mol Oncol. 2023 Dec;17 (12) :2618-2636.|Mol Pharm. 2021 Jul 5;18 (7) :2495-2506.|Nat Commun. 2023 Apr 24;14 (1) :2342.|Nat Commun. 2023 Mar 28;14 (1) :1726.|Nat Commun. 2019 Apr 18;10 (1) :1812|Neurobiol Dis. 2020 Aug;142:104961.|Oncogene. 2017 May 11;36 (19) :2643-2654.|Oncogene. 2021 Apr;40 (14) :2596-2609.|Oncogene. 2021 Jul;40 (30) :4884-4893.|Oncogene. 2022 May;41 (22) :3064-3078.|Oncogene. 2023 Sep;42 (39) :2869-2877.|Oncol Rep. 2016 Dec;36 (6) :3588-3596.|Oncol Rep. 2021 Mar;45 (3) :1306-1314.|Oncotarget. 2017 Dec 2;8 (68) :112313-112329.|Patent. US20240344020A1|Patent. US20240344020A1.|Pharmaceuticals (Basel) . 2024 Dec 16;17 (12) :1696.|PLoS One. 2018 Jun 14;13 (6) :e0199208.|PLoS One. 2024 Nov 1;19 (11) :e0308647.|PLoS Pathog. 2024 Aug 5;20 (8) :e1012437.|Proc Natl Acad Sci U S A. 2024 May 21;121 (21) :e2403685121.|Proteomes. 2023 Jun 2;11 (2) :20.|Res Sq. 2025 Jun 24:rs.3.rs-6456987.|Research Square Preprint. 2021 May.|Research Square Preprint. 2022 Jun.|Research Square Preprint. 2024 Nov 26.|Saudi Pharm J. 2023 Oct;31 (10) :101756.|Sci Transl Med. 2018 Jul 18;10 (450) :eaaq1093.|SSRN. 31 Aug 2021.|Stem Cell Res Ther. 2022 Jun 21;13 (1) :269.|Stem Cells. 2022 May 27;40 (5) :508-522.|Thorac Cancer. 2020 Oct;11 (10) :2858-2866.|Virulence. 2022 Dec;13 (1) :1849-1867.|Viruses. 2020 Jun 10;12 (6) :628.
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
